{"disease":{"id":"nash","name":"nash"},"drugs":{"marketed":[{"drug_id":"resmetirom","indication_name":"Noncirrhotic Nonalcoholic Steatohepatitis (NASH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RESMETIROM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Thyroid Hormone Receptor beta Agonist [EPC]","quality_score":30,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"pf-05221304","indication_name":"Nonalcoholic steatohepatitis (NASH)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-05221304","generic_name":"pf-05221304","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Acetyl-CoA carboxylase (ACC1 and ACC2)","drug_class":"Acetyl-CoA carboxylase inhibitor","quality_score":27,"revenue":null,"mechanism":"Selective inhibitor of acetyl-CoA carboxylase (ACC1/ACC2) that reduces hepatic lipogenesis and promotes fatty acid oxidation."},{"drug_id":"pf-05221304","indication_name":"NASH with fibrosis","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-05221304","generic_name":"pf-05221304","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Acetyl-CoA carboxylase (ACC1 and ACC2)","drug_class":"Acetyl-CoA carboxylase inhibitor","quality_score":27,"revenue":null,"mechanism":"Selective inhibitor of acetyl-CoA carboxylase (ACC1/ACC2) that reduces hepatic lipogenesis and promotes fatty acid oxidation."},{"drug_id":"pf-05221304","indication_name":"NAFLD/NASH (combination therapy with DGAT2i)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-05221304","generic_name":"pf-05221304","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Acetyl-CoA carboxylase (ACC1 and ACC2)","drug_class":"Acetyl-CoA carboxylase inhibitor","quality_score":27,"revenue":null,"mechanism":"Selective inhibitor of acetyl-CoA carboxylase (ACC1/ACC2) that reduces hepatic lipogenesis and promotes fatty acid oxidation."}],"offLabel":[],"totalMarketed":1,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT07241195","title":"A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"The Affiliated Hospital of Hangzhou Normal University","has_results":false},{"nct_id":"NCT03151473","title":"Longitudinal Observational Study Of Chinese With NAFLD/NASH","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Humanity and Health Research Centre","has_results":false},{"nct_id":"NCT07336563","title":"ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Jarosław Drobnik","has_results":false},{"nct_id":"NCT04442334","title":"The European NAFLD Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Newcastle University","has_results":false},{"nct_id":"NCT05857319","title":"Study Consortium for Evaluation of RNPC Program in Obese and Overweight Patients (SCOOP-RNPC)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Groupe Éthique et Santé","has_results":false},{"nct_id":"NCT03760172","title":"Immunomediated Non-alcoholic SteaTohepatitis; Prevalence and Characterization. INSTInCT Study","phase":"","overall_status":"UNKNOWN","enrollment_count":7300,"lead_sponsor_name":"Instituto de Investigación Marqués de Valdecilla","has_results":false},{"nct_id":"NCT05423327","title":"Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)","phase":"NA","overall_status":"TERMINATED","enrollment_count":5311,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT04371042","title":"PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT02548351","title":"Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":2477,"lead_sponsor_name":"Intercept Pharmaceuticals","has_results":true},{"nct_id":"NCT06123858","title":"Non-alcoholic Steatohepatitis Registry Platform Study","phase":"","overall_status":"TERMINATED","enrollment_count":1122,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03726827","title":"A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Populations","phase":"","overall_status":"COMPLETED","enrollment_count":1006,"lead_sponsor_name":"Fatty liver Foundation","has_results":false},{"nct_id":"NCT04849728","title":"A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Inventiva Pharma","has_results":false},{"nct_id":"NCT07502755","title":"Non-invasive Tests for Non-alcoholic Steato-hepatitis","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":828,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT03289897","title":"Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan","phase":"NA","overall_status":"COMPLETED","enrollment_count":801,"lead_sponsor_name":"Perspectum","has_results":false},{"nct_id":"NCT04841057","title":"Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":750,"lead_sponsor_name":"University of Missouri-Columbia","has_results":false},{"nct_id":"NCT04232293","title":"Screening of Liver Fibrosis Using Blood Tests in Patients With Type 2 Diabetes Mellitus","phase":"NA","overall_status":"COMPLETED","enrollment_count":722,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT06315361","title":"DIAbetes and NAFLD","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04653103","title":"NASH in Subjects With Different Classes of Obesity","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Catholic University of the Sacred Heart","has_results":false},{"nct_id":"NCT06523179","title":"Evaluation of Risk of hEpatocellular Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","has_results":false},{"nct_id":"NCT05479721","title":"LITMUS Imaging Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":450,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT06888310","title":"Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":408,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT07122700","title":"Evaluation of Non-Invasive Tests for Metabolic Liver Disease","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Foundation for the National Institutes of Health","has_results":false},{"nct_id":"NCT07180745","title":"Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Badr University","has_results":false},{"nct_id":"NCT06348563","title":"AGED Diagnostics Liver Disease Assessment","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Active Genomes Expressed Diagnostics, Corp","has_results":false},{"nct_id":"NCT05023044","title":"Nonalcoholic Fatty Liver Disease in HIV Database","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT04365868","title":"Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":357,"lead_sponsor_name":"Galectin Therapeutics Inc.","has_results":false},{"nct_id":"NCT02855164","title":"Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":350,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03439189","title":"Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14","phase":"","overall_status":"COMPLETED","enrollment_count":343,"lead_sponsor_name":"Meridian Bioscience, Inc.","has_results":true},{"nct_id":"NCT03858920","title":"The Liver in the World Trade Center Health Program General Responder Cohort and Controls","phase":"","overall_status":"COMPLETED","enrollment_count":340,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT04366999","title":"Effectiveness of Bariatric Surgery for NAFLD/NASH","phase":"","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT05499949","title":"The Franciscus Obesity NASH Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Franciscus Gasthuis","has_results":false},{"nct_id":"NCT04255069","title":"A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"TaiwanJ Pharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT03778411","title":"Non-invasive Evaluation of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease by Assessment of Spleen Stiffness Using VCTE by FibroScan.","phase":"","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT04771273","title":"A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04052516","title":"A Phase 2b Study of Icosabutate in Fatty Liver Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":280,"lead_sponsor_name":"NorthSea Therapeutics B.V.","has_results":true},{"nct_id":"NCT02538874","title":"A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":275,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT01672879","title":"Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":259,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT02443116","title":"Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":254,"lead_sponsor_name":"NGM Biopharmaceuticals, Inc","has_results":true},{"nct_id":"NCT06879236","title":"Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease","phase":"","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04173065","title":"A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":248,"lead_sponsor_name":"Viking Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03008070","title":"Phase 2b Study in NASH to Assess IVA337","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":247,"lead_sponsor_name":"Inventiva Pharma","has_results":true},{"nct_id":"NCT04065841","title":"Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":234,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05669677","title":"Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease","phase":"","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT04880031","title":"A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":231,"lead_sponsor_name":"Boston Pharmaceuticals","has_results":false},{"nct_id":"NCT05327127","title":"Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":228,"lead_sponsor_name":"Kowa Research Institute, Inc.","has_results":false},{"nct_id":"NCT04054310","title":"Non-Invasive Quantification of Liver Health in NASH (N-QUAN)","phase":"NA","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Perspectum","has_results":false},{"nct_id":"NCT04561895","title":"Adipokine Genetic Variations in predictingNAFLD Progression to NASH in Egyptian Patients","phase":"","overall_status":"COMPLETED","enrollment_count":224,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT04929483","title":"Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"89bio, Inc.","has_results":true},{"nct_id":"NCT01672866","title":"Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":222,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT06364462","title":"Precise Evaluation Criteria for Histological Regression of NASH Fibrosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":220,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}